7月1日,国家药监局的一纸公告在医药行业激起波澜:56个药品注册证书被集中注销,其中进口批文占比超过50%,涉及葛兰素史克的乳腺癌药物甲苯磺酸拉帕替尼片、辉瑞的利奈唑胺葡萄糖注射液、安进的依洛尤单抗注射液等知名原研药。这是跨国药企在中国市场的战略转型的缩影。在专利悬崖和集采压力下,外资药企正集体剥离成熟药品资产,向高利润蓝海撤退。这场持续蔓延的退市潮为腾挪出巨大的市场真空带,更倒逼着中国医药市场...
Source Link7月1日,国家药监局的一纸公告在医药行业激起波澜:56个药品注册证书被集中注销,其中进口批文占比超过50%,涉及葛兰素史克的乳腺癌药物甲苯磺酸拉帕替尼片、辉瑞的利奈唑胺葡萄糖注射液、安进的依洛尤单抗注射液等知名原研药。这是跨国药企在中国市场的战略转型的缩影。在专利悬崖和集采压力下,外资药企正集体剥离成熟药品资产,向高利润蓝海撤退。这场持续蔓延的退市潮为腾挪出巨大的市场真空带,更倒逼着中国医药市场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.